المؤلفون: Kathleen N. Moore, Alexandra Leary, Dominique Berton, Christina P. Opperman, Maria Del Pilar Estevez-Diz, Laurence Gladieff, Marek Ancukiewicz, Anne-Claire Hardy-Bessard, Frédéric Selle, Isabelle Ray-Coquard, Waldo Ortuzar Feliu, Carlos Rojas, Bradley J. Monk, David M. O'Malley, Ana Oaknin, Carla Rameri Alexandre Silva de Azevedo, Leslie M Randall, Jérôme Alexandre

المساهمون: Institut Català de la Salut, [O'Malley DM] The Ohio State University, James Comprehensive Cancer Center, Columbus, OH, United States. [Oaknin A] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Monk BJ] Arizona Oncology (US Oncology Network), Creighton University School of Medicine, Phoenix, AZ, United States. [Selle F] Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France. [Rojas C] Centro de Investigacion Clinica, Bradford Hill, Santiago, Chile. [Gladieff L] Institut Claudius Regaud-Institut Universitaire du Cancer (IUCT)-Oncopole, Toulouse, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Adult, Diarrhea, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Uterine Cervical Neoplasms, Phases of clinical research, Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Antibodies, Monoclonal, Humanized, Gastroenterology, Drug Administration Schedule, Coll uterí - Càncer - Tractament, Internal medicine, Clinical endpoint, Humans, Medicine, Infusions, Intravenous, Adverse effect, Immune Checkpoint Inhibitors, Response Evaluation Criteria in Solid Tumors, Aged, Aged, 80 and over, Enterocolitis, Cervical cancer, business.industry, Obstetrics and Gynecology, Immunotherapy, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Oncology, Medicaments - Eficàcia, Avaluació de resultats (Assistència sanitària), Female, Neoplasm Recurrence, Local, medicine.symptom, business, neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino [ENFERMEDADES]

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::305b8fceb47334a9c726d838350b5dd9Test
https://doi.org/10.1016/j.ygyno.2021.08.018Test

المؤلفون: Seock-Ah Im, Patrick Neven, John Crown, Rosa-Maria Espadero, Noelia Martínez, Yen-Shen Lu, Jonas Bergh, Thomas Bogenrieder, J. Alejandro Pérez-Fidalgo, Peter Schmid, Guy Jerusalem, Laura Schlieker, Serafin Morales, Dennis Chin-Lun Huang, Douglas Adamson, Javier Cortes, Anthony Gonçalves, Keun Seok Lee, Marie-Paule Sablin, Aleix Prat

المساهمون: Queen Mary University of London (QMUL), Institut Curie [Paris], Karolinska University Hospital [Stockholm], Seoul National University Hospital, National Taiwan University Hospital [Taipei], Ramon & Cajal University Hospital, UZ Leuven - campus Gasthuisberg, Hospital of National Cancer Center [Goyang], Hospital Universitario Arnau de Vilanova de Lleida, Biomedical Research Institute [Valencia, Spain] (INCLIVA ), Ninewells Hospital and Medical School [Dundee], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centre Hospitalier Universitaire de Liège (CHU-Liège), Boehringer Ingelheim Pharma GmbH & Co. KG, St Vincent's University Hospital, Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Institute of Oncology Prof. Dr. Alexandru Trestioreanu (IOB), Institut Català de la Salut, [Schmid P] Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. [Sablin MP] Department of Drug Development and Innovation, Institut Curie, Paris, France. [Bergh J] Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden. [Im SA] Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. [Lu YS] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. [Martínez N] Department of Oncology, Ramon y Cajal University Hospital, Madrid, Spain. [Cortés J] Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Oncology, IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Breast Cancer Research
Breast Cancer Research, 2021, 23 (1), pp.8. ⟨10.1186/s13058-020-01382-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research : BCR
Scientia

مصطلحات موضوعية: Oncology, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Exemestane, Antineoplastic Combined Chemotherapy Protocols, terapéutica::farmacoterapia::farmacoterapia combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Clinical endpoint, Insulin-like growth factor, Neoplasm Metastasis, Aged, 80 and over, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], 0303 health sciences, education.field_of_study, Hazard ratio, Therapeutics::Drug Therapy::Drug Therapy, Combination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Disease Management, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Metastatic breast cancer, Treatment Outcome, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Receptors, Progesterone, Life Sciences & Biomedicine, Research Article, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Population, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Hormone receptor-positive, Humans, Xentuzumab, Everolimus, education, Adverse effect, Aged, Neoplasm Staging, 030304 developmental biology, Science & Technology, business.industry, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Androstadienes, chemistry, Mama - Càncer - Tractament, Medicaments - Eficàcia, business, HER2-negative

وصف الملف: application/pdf; Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fb312f1fe2cc964111c140ba48f774Test
https://hal.science/hal-03630009Test

المؤلفون: Filipa Aragão, Joaquim Peraire, Juan Berenguer, Pere Domingo, Belén de la Fuente, Sophie Marguet, María José Galindo, María Dolores Merino, Vicente Estrada, Fernando Lozano, Josefina Garcia, Ramón Teira, Esteban Ribera, Nadia Abdulghani, Helena Diaz-Cuervo, Bernardino Roca, Maria Jose Muñoz, Marta Montero, Elisa Martínez, M. Antonia Sepúlveda, Alberto Romero, Nuria Espinosa, Elisabeth Deig, Paloma Geijo

المساهمون: Institut Català de la Salut, [Teira R] Hospital de Sierrallana, Torrelavega, Spain. [Diaz-Cuervo H] Gilead Sciences, Medical Affairs, Stockley Park HEOR, Spain. [Aragão F] Maple Health Group, New York, New York, United States of America. NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisboa, Portugal. [Marguet S] Amaris Consulting, Health Economics and Market Access (HEMA), Levallois-Perret, France. [de la Fuente B] Hospital de Cabueñes, Gijón, Spain. [Muñoz MJ] Hospital de Basurto, Bilbao, Spain. [Ribera E] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: PLoS ONE
PLoS ONE, Vol 16, Iss 4, p e0249515 (2021)
PLoS One
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Scientia
Plos One
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

مصطلحات موضوعية: 0301 basic medicine, DOLUTEGRAVIR, RNA viruses, Male, Viral Diseases, HIV Infections, Pathology and Laboratory Medicine, Toxicology, Biochemistry, chemistry.chemical_compound, 0302 clinical medicine, Medical Conditions, ANTIRETROVIRAL THERAPY, Immunodeficiency Viruses, Nucleic Acids, terapéutica::farmacoterapia::farmacoterapia combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Medicine and Health Sciences, Public and Occupational Health, 030212 general & internal medicine, Prospective Studies, INFECTED PATIENTS, Multidisciplinary, Protease Inhibitor Therapy, Hazard ratio, Therapeutics::Drug Therapy::Drug Therapy, Combination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], HIV diagnosis and management, Standard of Care, Middle Aged, Viral Load, Vaccination and Immunization, AIDS, Drug Combinations, Infectious Diseases, Medical Microbiology, Research Design, Viral Pathogens, Dolutegravir, Cohort, Viruses, Medicine, Reverse Transcriptase Inhibitors, Female, virus::virus ARN::Retroviridae::Lentivirus::Lentivirus de los primates::VIH [ORGANISMOS], Pathogens, Research Article, medicine.medical_specialty, PHASE-3, Clinical Research Design, Anti-HIV Agents, Science, 030106 microbiology, Immunology, Antiretroviral Therapy, Research and Analysis Methods, Microbiology, 03 medical and health sciences, Antiviral Therapy, Internal medicine, Retroviruses, medicine, Humans, Microbial Pathogens, Survival analysis, SUPPRESSION, Retrospective Studies, Toxicity, Proportional hazards model, business.industry, Lentivirus, Organisms, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Biology and Life Sciences, HIV, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Confidence interval, Diagnostic medicine, Discontinuation, Regimen, chemistry, Medicaments - Eficàcia, Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV [ORGANISMS], HIV-1, RNA, Preventive Medicine, Adverse Events, Medicaments - Administració, business, Persones seropositives

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::881d13bfafe5b7088fea060081bd6fd9Test
http://europepmc.org/articles/PMC8031389Test

المؤلفون: Begoña Olmedilla-Alonso, Maria Hernandez, Alfredo García-Layana, Miguel A Zapata, Sergio Recalde, Maximino Abraldes, João Nascimento, Jose Juan Escobar-Barranco, M.C. López-Sabater, Silvia Mendez-Martinez, Rufino Silva, Pilar Calvo, Mariana Caballero Arredondo, Nieves Pardiñas-Barón, Patricia Fernandez-Robredo, Emiliano Hernández-Galilea

المساهمون: Institut Català de la Salut, [García-Layana A, Recalde S, Hernandez M] Retinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clínica Universidad de Navarra, 31008 Pamplona, Spain. Navarra Institute for Health Research, IdiSNA, 31008 Pamplona, Spain. Red Temática de Investigación Cooperativa Sanitaria en Enfer-Medades Oculares (Oftared), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Abraldes MJ] Red Temática de Investigación Cooperativa Sanitaria en Enfer-Medades Oculares (Oftared), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Nascimento J] Retinal Department, Ophthalmology, Retina Lisbon Institut, 1050-085 Lisbon, Portugal. [Hernández-Galilea E] Department of Ophthalmology, University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain. [Zapata MA] Servei d’Oftalmologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Laboratoires Théa, European Commission, Instituto de Salud Carlos III

المصدر: Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Scientia
Nutrients, Vol 13, Iss 1253, p 1253 (2021)
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Digital.CSIC. Repositorio Institucional del CSIC
Nutrients
Volume 13
Issue 4

مصطلحات موضوعية: 0301 basic medicine, Male, Lutein, Visual acuity, Eye disease, Visual Acuity, Xanthophylls, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Gastroenterology, law.invention, Retilut®, chemistry.chemical_compound, Macular Degeneration, 0302 clinical medicine, Randomized controlled trial, law, chemistry.chemical_classification, Aged, 80 and over, Nutrition and Dietetics, carotenoids, food and beverages, Diabetic retinopathy, Middle Aged, Phenylethyl Alcohol, inflammatory markers, Zeaxanthin, Treatment Outcome, Female, medicine.symptom, lcsh:Nutrition. Foods and food supply, Polyunsaturated fatty acid, polyunsaturated fatty acids, medicine.medical_specialty, Nutritional Supplementation, Docosahexaenoic Acids, Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], lcsh:TX341-641, Article, Theavit®, 03 medical and health sciences, Zeaxanthins, Internal medicine, medicine, Humans, age-related macular degeneration, Aged, business.industry, Age-related macular degeneration, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Nutrients, medicine.disease, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Carotenoids, eye diseases, oftalmopatías::enfermedades de la retina::degeneración retiniana::degeneración macular [ENFERMEDADES], 030104 developmental biology, AREDS, chemistry, Resveratrol, Dietary Supplements, 030221 ophthalmology & optometry, angiogenic factors at month 12, Medicaments - Eficàcia, Avaluació de resultats (Assistència sanitària), Degeneració macular - Tractament, business, Food Science

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::900fd947ba5d8f723e658c77a5a301c0Test
http://zaguan.unizar.es/record/118791Test

المؤلفون: Marie Linder, Christine L. Bui, Albert Roso-Llorach, Alejandro Arana, Oliver Scholle, Francisca González-Rubio, Beatriz Poblador-Plou, Alexandra Prados-Torres, Maria Giner-Soriano, Jordi Castellsague, Brian Calingaert, Clara Laguna, Susana Perez-Gutthann

المساهمون: [Castellsague J, Arana A, Perez-Gutthan S] Epidemiology, RTI Health Solutions, Barcelona, Spain. [Poblador-Plou B, Laguna C, Gonzalez-Rubio F, Prados-Torres A] Aragon Health Sciences Institute (IACS), IISAragon, Hospital Universitario Miguel Servet,University of Zaragoza, Zaragoza, Spain. [Giner-Soriano M, Roso-Llorach A] Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. [Linder M] Centre for Pharmacoepidemiology, Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. [Scholle O] Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany. [Calingaert B, Bui C] Epidemiology, RTI Health Solutions, Research Triangle Park, NC, USA, IDIAP Jordi Gol

المصدر: Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Pharmacoepidemiology and Drug Safety
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Pharmacoepidemiology and drug safety, 27(9):953-961
Recercat. Dipósit de la Recerca de Catalunya

مصطلحات موضوعية: Male, Study Characteristics::Comparative Study [PUBLICATION CHARACTERISTICS], pharmacoepidemiology, database study, Databases, Factual, Epidemiology, medicine.medical_treatment, enfermedades cardiovasculares::enfermedades vasculares::arteriopatías oclusivas::arteriosclerosis::claudicación intermitente [ENFERMEDADES], Smoking Prevention, 030204 cardiovascular system & hematology, Other subheadings::Other subheadings::/drug therapy [Other subheadings], características del estudio::estudio comparativo [CARACTERÍSTICAS DE PUBLICACIONES], 0302 clinical medicine, Germany, Preventive Health Services, Health care, Prevalence, Original Report, Pharmacology (medical), 030212 general & internal medicine, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores], Claudicació intermitent - Tractament, Smoking, intermittent claudication, Pharmacoepidemiology, Methods observational, Cilostazol, Cardiovascular Diseases, Cohort, Female, medicine.symptom, medicine.drug, Características de los Estudios::Estudio Comparativo [CARACTERÍSTICAS DE PUBLICACIONES], Cardiovascular Diseases::Vascular Diseases::Arterial Occlusive Diseases::Arteriosclerosis::Intermittent Claudication [DISEASES], CYP2C19, peripheral artery disease, Claudicació intermitent - Estudi de casos, Intermittent claudication, 03 medical and health sciences, Environmental health, Original Reports, medicine, Humans, risk minimization, Risk minimization, Peripheral artery disease, Database study, Aged, Drug Labeling, Sweden, Dose-Response Relationship, Drug, business.industry, Health Plan Implementation, United Kingdom, Spain, Medicaments - Eficàcia, Smoking cessation, business, Platelet Aggregation Inhibitors, Program Evaluation

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dff33aff5c6cab1a57719054f34d9b0Test
https://hdl.handle.net/11351/3804Test